File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1097/PGP.0b013e3181e7cc66
- Scopus: eid_2-s2.0-78149285342
- PMID: 20881859
- WOS: WOS:000283264400006
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Ovarian clear cell carcinoma with choriocarcinomatous differentiation: Report of a rare and aggressive tumor
Title | Ovarian clear cell carcinoma with choriocarcinomatous differentiation: Report of a rare and aggressive tumor |
---|---|
Authors | |
Keywords | choriocarcinoma clear cell carcinoma neoadjuvant chemotherapy nongestatational choriocarcinoma ovarian carcinoma |
Issue Date | 2010 |
Publisher | Lippincott Williams & Wilkins. The Journal's web site is located at http://www.intjgynpathology.com |
Citation | International Journal Of Gynecological Pathology, 2010, v. 29 n. 6, p. 539-545 How to Cite? |
Abstract | Ovarian epithelial tumors of nongerm cell origin with true choriocarcinomatous differentiation are rare. To date, there are only 5 documented cases in the literature. In the reported cases, the epithelial component was of mixed cell types or of mucinous differentiation. To the best of our knowledge, an ovarian carcinoma exclusively of clear cell differentiation coexisting with a pure choriocarcinoma has not been reported earlier. A 48-year-old postmenopausal woman was found to have a large pelvic mass with lung and liver metastases. Trucut biopsy of the mass showed a poorly differentiated carcinoma that was immunoreactive for CK7 and hCG. She received 6 cycles of neoadjuvant chemotherapy that included 3 cycles of etoposide/cisplatin and 3 cycles of paclitaxel/etoposide-paclitaxel/carboplatin (TE/TP) with partial response. Debulking surgery was carried out subsequently. Pathologic examination showed an ovarian clear cell carcinoma with a second component of choriocarcinoma in which the bilaminar growth pattern of cytotrophoblast and syncytiotrophoblasts was striking. Despite additional therapy, which included 2 cycles of TE/TP and 2 cycles of gemcitabine/taxotere, the disease progressed and the patient died 11 months postoperatively. This report showed that ovarian clear cell carcinoma with choriocarcinomatous differentiation is a highly aggressive tumor and has a very poor prognosis. Nonetheless, there may be a role for neoadjuvant chemotherapy that targets both the clear cell and the choriocarcinoma components to reduce the volume of the disease before debulking surgery. © 2010 International Society of Gynecological Pathologists. |
Persistent Identifier | http://hdl.handle.net/10722/135675 |
ISSN | 2023 Impact Factor: 1.6 2023 SCImago Journal Rankings: 0.640 |
ISI Accession Number ID | |
References |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Hu, YJ | en_HK |
dc.contributor.author | Ip, PPC | en_HK |
dc.contributor.author | Chan, KKL | en_HK |
dc.contributor.author | Tam, KF | en_HK |
dc.contributor.author | Ngan, HYS | en_HK |
dc.date.accessioned | 2011-07-27T01:39:12Z | - |
dc.date.available | 2011-07-27T01:39:12Z | - |
dc.date.issued | 2010 | en_HK |
dc.identifier.citation | International Journal Of Gynecological Pathology, 2010, v. 29 n. 6, p. 539-545 | en_HK |
dc.identifier.issn | 0277-1691 | en_HK |
dc.identifier.uri | http://hdl.handle.net/10722/135675 | - |
dc.description.abstract | Ovarian epithelial tumors of nongerm cell origin with true choriocarcinomatous differentiation are rare. To date, there are only 5 documented cases in the literature. In the reported cases, the epithelial component was of mixed cell types or of mucinous differentiation. To the best of our knowledge, an ovarian carcinoma exclusively of clear cell differentiation coexisting with a pure choriocarcinoma has not been reported earlier. A 48-year-old postmenopausal woman was found to have a large pelvic mass with lung and liver metastases. Trucut biopsy of the mass showed a poorly differentiated carcinoma that was immunoreactive for CK7 and hCG. She received 6 cycles of neoadjuvant chemotherapy that included 3 cycles of etoposide/cisplatin and 3 cycles of paclitaxel/etoposide-paclitaxel/carboplatin (TE/TP) with partial response. Debulking surgery was carried out subsequently. Pathologic examination showed an ovarian clear cell carcinoma with a second component of choriocarcinoma in which the bilaminar growth pattern of cytotrophoblast and syncytiotrophoblasts was striking. Despite additional therapy, which included 2 cycles of TE/TP and 2 cycles of gemcitabine/taxotere, the disease progressed and the patient died 11 months postoperatively. This report showed that ovarian clear cell carcinoma with choriocarcinomatous differentiation is a highly aggressive tumor and has a very poor prognosis. Nonetheless, there may be a role for neoadjuvant chemotherapy that targets both the clear cell and the choriocarcinoma components to reduce the volume of the disease before debulking surgery. © 2010 International Society of Gynecological Pathologists. | en_HK |
dc.language | eng | en_US |
dc.publisher | Lippincott Williams & Wilkins. The Journal's web site is located at http://www.intjgynpathology.com | en_HK |
dc.relation.ispartof | International Journal of Gynecological Pathology | en_HK |
dc.subject | choriocarcinoma | en_HK |
dc.subject | clear cell carcinoma | en_HK |
dc.subject | neoadjuvant chemotherapy | en_HK |
dc.subject | nongestatational choriocarcinoma | en_HK |
dc.subject | ovarian carcinoma | en_HK |
dc.subject.mesh | Adenocarcinoma, Clear Cell - pathology - therapy | - |
dc.subject.mesh | Antineoplastic Agents - therapeutic use | - |
dc.subject.mesh | Choriocarcinoma, Non-gestational - pathology - therapy | - |
dc.subject.mesh | Gynecologic Surgical Procedures | - |
dc.subject.mesh | Ovarian Neoplasms - pathology - therapy | - |
dc.title | Ovarian clear cell carcinoma with choriocarcinomatous differentiation: Report of a rare and aggressive tumor | en_HK |
dc.type | Article | en_HK |
dc.identifier.email | Chan, KKL:kklchan@hkucc.hku.hk | en_HK |
dc.identifier.email | Ngan, HYS:hysngan@hkucc.hku.hk | en_HK |
dc.identifier.authority | Chan, KKL=rp00499 | en_HK |
dc.identifier.authority | Ngan, HYS=rp00346 | en_HK |
dc.description.nature | link_to_subscribed_fulltext | - |
dc.identifier.doi | 10.1097/PGP.0b013e3181e7cc66 | en_HK |
dc.identifier.pmid | 20881859 | - |
dc.identifier.scopus | eid_2-s2.0-78149285342 | en_HK |
dc.identifier.hkuros | 186767 | en_US |
dc.identifier.hkuros | 188236 | en_US |
dc.relation.references | http://www.scopus.com/mlt/select.url?eid=2-s2.0-78149285342&selection=ref&src=s&origin=recordpage | en_HK |
dc.identifier.volume | 29 | en_HK |
dc.identifier.issue | 6 | en_HK |
dc.identifier.spage | 539 | en_HK |
dc.identifier.epage | 545 | en_HK |
dc.identifier.isi | WOS:000283264400006 | - |
dc.publisher.place | United States | en_HK |
dc.identifier.scopusauthorid | Hu, YJ=37031077400 | en_HK |
dc.identifier.scopusauthorid | Ip, PPC=7003622683 | en_HK |
dc.identifier.scopusauthorid | Chan, KKL=8655666700 | en_HK |
dc.identifier.scopusauthorid | Tam, KF=7201692816 | en_HK |
dc.identifier.scopusauthorid | Ngan, HYS=34571944100 | en_HK |
dc.identifier.issnl | 0277-1691 | - |